Pertuzumab, a recombinant humanized monoclonal anti-HER2 antibody, sterically blocks HER2 heterodimerization with other HER receptors, especially HER3, and was approved by the FDA in 2012 for breast cancer therapy12. Here, ERBB2 is linked to breast cancer.